Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination latency-reversing therapy for HIV reservoir reactivation
NL-OMON60893Phase 2Completed
- Sponsor
- Erasmus MC
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pyrimethamine, lenalidomide and panobinostat in Human immunodeficiency virus infection type 1, sponsored by Erasmus MC. Primary endpoints: Cell-associated HIV RNA fold change at 6 and 24 hours and Treatment-related adverse events. Started Jul 2024; status: completed.
02
Drugs
pyrimethaminelenalidomidepanobinostat
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on NL-OMON60893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60893.